03:12 PM EST, 11/11/2025 (MT Newswires) -- Dogwood Therapeutics ( DWTX ) enrolled the first 100 patients in its Phase 2b study evaluating Halneuron for chemotherapy-induced neuropathic pain.

An interim analysis is scheduled for Q4 based on participants who complete or exit the four-week trial, the company said Tuesday in a statement.

The study remains on track to recruit 200 patients, with final results expected by mid-2026, the company said.

Patients receive eight doses of Halneuron or placebo over 14 days, followed by assessments of pain, sleep, fatigue, and quality of life.

Price: 5.65, Change: +0.09, Percent Change: +1.53